Citigroup Inc. Sells 24,449 Shares of Waters Corporation $WAT

Citigroup Inc. reduced its stake in shares of Waters Corporation (NYSE:WAT) by 43.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,047 shares of the medical instruments supplier’s stock after selling 24,449 shares during the quarter. Citigroup Inc. owned approximately 0.05% of Waters worth $9,608,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. ANTIPODES PARTNERS Ltd purchased a new position in shares of Waters during the third quarter worth approximately $26,000. Tredje AP fonden boosted its holdings in shares of Waters by 44.1% in the third quarter. Tredje AP fonden now owns 7,434 shares of the medical instruments supplier’s stock valued at $2,229,000 after purchasing an additional 2,276 shares during the period. Stevens Capital Management LP bought a new position in Waters in the third quarter worth approximately $501,000. Raiffeisen Bank International AG grew its stake in Waters by 3.1% in the third quarter. Raiffeisen Bank International AG now owns 1,742 shares of the medical instruments supplier’s stock worth $504,000 after purchasing an additional 52 shares in the last quarter. Finally, Alberta Investment Management Corp purchased a new position in Waters during the 3rd quarter worth $4,677,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Waters Stock Down 1.2%

Shares of Waters stock opened at $318.99 on Monday. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37. The company has a market cap of $31.29 billion, a P/E ratio of 29.62, a PEG ratio of 2.20 and a beta of 1.20. The firm’s 50 day moving average price is $368.77 and its 200-day moving average price is $351.02. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $414.15.

Waters (NYSE:WAT) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share for the quarter, beating the consensus estimate of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The company had revenue of $932.36 million during the quarter, compared to the consensus estimate of $928.17 million. During the same period last year, the firm earned $4.10 earnings per share. Waters’s revenue was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, sell-side analysts predict that Waters Corporation will post 12.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Waters in a report on Wednesday, January 21st. Wells Fargo & Company lowered their price objective on shares of Waters from $415.00 to $355.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 11th. TD Cowen reiterated a “hold” rating on shares of Waters in a report on Wednesday, November 5th. Morgan Stanley cut their target price on shares of Waters from $423.00 to $350.00 and set an “equal weight” rating on the stock in a research report on Sunday, February 22nd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $440.00 price target on shares of Waters in a research report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Waters has an average rating of “Moderate Buy” and an average target price of $393.84.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.